Men's Health News

RSS

Prostrate cancer patients can benefit from new MRI-ultrasound fusion

Targeted biopsy, a major advance in prostate cancer diagnostics, was detailed by a UCLA team in the current issue of Urologic Oncology. The new technology fuses MRI with real-time 3D ultrasound, providing an exacting method to obtain biopsy specimens from suspicious areas in the prostate.

12 May 2011

Novel ultrasound-targeted microbubble-destruction technology advances cure for prostate cancer

Cancer researchers are a step closer to finding a cure for advanced prostate cancer after effectively combining an anti-cancer drug with a viral gene therapy in vivo using novel ultrasound-targeted microbubble-destruction (UTMD) technology.

11 May 2011

Researchers discover role of MAN2C1 protein in prostate cancer development

It's a disease affecting those closest to us - our fathers, brothers and sons. Prostate cancer impacts one in six men in Canada. Last year, roughly 24,600 men were diagnosed with the disease.

11 May 2011

Surgery reduces mortality risk of prostate cancer

A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer (even those with low-risk tumours) will die within 15 years. The results were published today in the New England Journal of Medicine.

6 May 2011

FDA approves new targeted therapy to treat men with advanced prostate cancer

The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.

3 May 2011

FDA approves Perrigo's Minoxidil Foam, a generic version of Men's Rogaine Foam

Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter Minoxidil Foam, a generic version of Men's Rogaine Foam.

3 May 2011

New research sheds light on why young black males have high HIV infection rates

New research is shedding light on why young black males who have sex with males have among the highest rates of HIV infection in the United States, even though their reported use of condoms is similar to males of other racial and ethnic backgrounds.

2 May 2011

USHIFU announces results from clinical investigation of Sonablate HIFU to treat prostate cancer

USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.

30 Apr 2011

FDA approves Abbott's AndroGel for hypogonadism treatment in men

Abbott announced today that the U.S. Food and Drug Administration has approved AndroGel 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.

30 Apr 2011

Pelvic MRI scan identifies local recurrence of prostate cancer at low PSA levels

A pelvic MRI scan with IV contrast and rectal balloon is highly effective in identifying local recurrence even at low PSA values in prostate cancer patients with a rising or persistently elevated PSA after prostatectomy, according to a study presented April 29, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. The symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).

29 Apr 2011

Injecting tissue spacers reduces risk of radiation burns to rectum in prostate cancer patients

Injecting a tissue spacer in the prostate-rectal inter-space is an effective way to reduce the rectal dose for prostate cancer patients receiving radiation therapy, according to research presented April 30, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and Radiological Society of North America (RSNA).

29 Apr 2011

Men with high DHA levels may face risk of developing aggressive prostate cancer

The largest study ever to examine the association of dietary fats and prostate cancer risk has found what's good for the heart may not be good for the prostate.

26 Apr 2011

Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer

A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.

22 Apr 2011

IFFS and ESHRE support new standards for cross border reproductive care

The International Federation of Fertility Societies (IFFS) has been working with the European Society of Human Reproduction and Embryology (ESHRE) in support of the ESHRE Good Practice Guide for Cross Border Reproductive Care.

20 Apr 2011

Testosterone therapy for prostate cancer needs reevaluation: New study

The long-standing prohibition against testosterone therapy in men with untreated or low-risk prostate cancer merits reevaluation, according to a new study published in The Journal of Urology.

20 Apr 2011

First ever genome scan for womb cancer reveals genetic region that reduces risk of the disease

Scientists have carried out the first ever genome scan for womb cancer and discovered a genetic region that reduces risk of the disease, according to a study published in Nature Genetics.

18 Apr 2011

Penile extenders represent an effective lengthening method for men

Surgeons should encourage men who request penile lengthening surgery to try non-invasive methods first and, in some cases, consider therapy to help them feel more positive about their body.

18 Apr 2011

FDA accepts Teva's NDA filing of Bio-T-Gel for male hypogonadism

BioSante Pharmaceuticals, Inc. today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd.. The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.

15 Apr 2011

Sex in Australian prisons: the facts

We all know what goes on in prison. Or do we? A study examining sexual behaviour and sexual culture in jails in NSW and Queensland suggests that popular beliefs about prison sex are largely myths.

12 Apr 2011